ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

Ibrance has been leading the CDK4/6 inhibitor race thanks to its first-to-market status. But Eli Lilly’s Verzenio has now shown it could go where the Pfizer’s breast cancer drug previously couldn’t, in a trial win that one influential oncologist said will “change practice.”